Also trades as: HLS.TO (TSX) · $vol 0M
HLTRF OTC
HLS Therapeutics Inc.
1W: -1.4%
1M: +4.2%
3M: -8.3%
YTD: -19.8%
1Y: -27.6%
3Y: -37.8%
5Y: -80.8%
$2.75
-0.04 (-1.43%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$16M
+100.1% ▲
5Y CAGR: +11.4%
Capital Expenditures
$209K
-1360.8% ▼
5Y CAGR: -65.8%
Free Cash Flow
$16M
+97.9% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$2M
-205.1% ▼
Net Change in Cash
-$6M
-27.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$13M | -$24M | -$28M | -$20M | -$13M |
| Depreciation & Amort. | $30M | $34M | $33M | $23M | $22M |
| Stock-Based Comp. | $2M | $3M | -$538K | $2M | $0 |
| Change in Working Capital | -$3M | $2M | $5M | $1M | $5M |
| Other Non-Cash Items | -$1M | $2M | $6M | -$2M | $3M |
| Operating Cash Flow | $16M | $17M | $15M | $8M | $16M |
| — Investing Activities — | |||||
| Capital Expenditures | -$5M | -$10M | -$41K | -$15K | -$2M |
| Acquisitions (Net) | -$4M | $0 | $0 | -$2M | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $4M | -$10M | -$148K | $13M | $0 |
| Investing Cash Flow | -$5M | -$10M | -$189K | $12M | -$2M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$11M | -$441K | -$9M | -$22M | -$18M |
| Stock Repurchased | -$47K | -$998K | -$2M | -$600K | -$2M |
| Dividends Paid | -$5M | -$5M | -$2M | $0 | $0 |
| Other Financing | $5M | -$455K | -$1M | -$1M | -$625K |
| Financing Cash Flow | -$11M | -$7M | -$15M | -$23M | -$21M |
| Net Change in Cash | $567K | -$456K | $1M | -$4M | -$6M |
| Cash End of Period | $21M | $21M | $22M | $17M | $12M |
| Free Cash Flow | $12M | $7M | $16M | $8M | $16M |